Genomic and Precision Medicine
portes grátis
Genomic and Precision Medicine
Oncology
Willard, Huntington F; Ginsburg, Geoffrey S.; Strickler, John; McKinney, Matthew Stuart
Elsevier Science Publishing Co Inc
04/2022
378
Dura
Inglês
9780128006849
15 a 20 dias
750
Descrição não disponível.
1. Overview: The Cancer Genome Landscape
2. Application of Human Genome Information to Clinical Practice
3. Translating genome information into clinical practice and human health
4. Big Data and Translational Bioinformatics Genomic and Personalized Medicine
5. Health Risk Assessment and Family History
6. Clinical Decision Support
7. Overview of Policy, Ethical and Social Considerations
8. Lymphomas
9. Leukemias
10. Genomics of Lung Cancer
11. Breast Cancer
12. Ovarian Cancer
13. Colorectal Cancer
14. Prostate Cancer
15. Head and Neck Cancer
16. Brain Tumors and Gliomas
17. Melanoma
18. Metastatic Cancer
19. Bioinformatics and Personalized Cancer Care
20. Diagnostic-Therapeutic Combinations
21. Treatment Decisions and Cancer Mutations
22. Case Studies
2. Application of Human Genome Information to Clinical Practice
3. Translating genome information into clinical practice and human health
4. Big Data and Translational Bioinformatics Genomic and Personalized Medicine
5. Health Risk Assessment and Family History
6. Clinical Decision Support
7. Overview of Policy, Ethical and Social Considerations
8. Lymphomas
9. Leukemias
10. Genomics of Lung Cancer
11. Breast Cancer
12. Ovarian Cancer
13. Colorectal Cancer
14. Prostate Cancer
15. Head and Neck Cancer
16. Brain Tumors and Gliomas
17. Melanoma
18. Metastatic Cancer
19. Bioinformatics and Personalized Cancer Care
20. Diagnostic-Therapeutic Combinations
21. Treatment Decisions and Cancer Mutations
22. Case Studies
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
ALK; Actionable mutations; Acute leukemia; Acute myeloid leukemia; Angiogenesis; Antibody-dependent cellular cytotoxicity; BRAF; BRAF mutation; BRCA1/2; Biliary tract cancers; Biomarkers; Biomedical informatics; Bispecific target engagers (BiTEs); Burkitt lymphoma; CTLA-4; Cancer screening; Checkpoint inhibitor; Chimeric antigen receptor-modified T cells; Chimeric antigen receptor-modified T cells (CAR T); Cholangiocarcinoma; Chromatin; Chronic myeloid leukemia; Circulating tumor DNA; Colorectal cancer; Computer science; Cytogenetics; DMMR; DNA damage repair; DNA methylation; Data science; Diffuse large B-cell lymphoma; EGFR; Epigenetics; Epigenome; Epigenomics; Epithelial ovarian cancer; Esophageal cancer; Evaluation; FLT3; Family health history; Follicular lymphoma; Gallbladder cancer; Gastric cancer; Gene expression profile; Genomics; Germline mutations; HER2; Hepatocellular carcinoma; Heterogeneity; Histone modifications; Homologous recombination deficiency; IDH1; IDH2; Ibrutinib; Immune checkpoint blockade; Immune response; Immune therapy; Immunotherapy; KRAS; Kidney cancer; Lung cancer; Lymphoma; M1/M2 macrophages; MET; MSI-H; Mantle cell lymphoma; Melanoma; Metabolomics; Molecular alteration; Molecular diagnostics; Molecular heterogeneity; Molecular profiling; Molecular tumor board; Myeloid neoplasms; NRAS; NTRK; Next generation sequencing; Next-generation sequencing; PARP inhibitors; PD1/PD-L1; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Patient-entered data; Precision medicine; Precision oncology; Prevention; Prostate cancer; Proteomics; Qualitative research; RET; ROS1; Renal carcinoma; Research design; Risk assessment; Risk prediction; Sequencing; Small molecule inhibitor; Targeted therapy; Transcriptomics; Tumor mutational burden
1. Overview: The Cancer Genome Landscape
2. Application of Human Genome Information to Clinical Practice
3. Translating genome information into clinical practice and human health
4. Big Data and Translational Bioinformatics Genomic and Personalized Medicine
5. Health Risk Assessment and Family History
6. Clinical Decision Support
7. Overview of Policy, Ethical and Social Considerations
8. Lymphomas
9. Leukemias
10. Genomics of Lung Cancer
11. Breast Cancer
12. Ovarian Cancer
13. Colorectal Cancer
14. Prostate Cancer
15. Head and Neck Cancer
16. Brain Tumors and Gliomas
17. Melanoma
18. Metastatic Cancer
19. Bioinformatics and Personalized Cancer Care
20. Diagnostic-Therapeutic Combinations
21. Treatment Decisions and Cancer Mutations
22. Case Studies
2. Application of Human Genome Information to Clinical Practice
3. Translating genome information into clinical practice and human health
4. Big Data and Translational Bioinformatics Genomic and Personalized Medicine
5. Health Risk Assessment and Family History
6. Clinical Decision Support
7. Overview of Policy, Ethical and Social Considerations
8. Lymphomas
9. Leukemias
10. Genomics of Lung Cancer
11. Breast Cancer
12. Ovarian Cancer
13. Colorectal Cancer
14. Prostate Cancer
15. Head and Neck Cancer
16. Brain Tumors and Gliomas
17. Melanoma
18. Metastatic Cancer
19. Bioinformatics and Personalized Cancer Care
20. Diagnostic-Therapeutic Combinations
21. Treatment Decisions and Cancer Mutations
22. Case Studies
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
ALK; Actionable mutations; Acute leukemia; Acute myeloid leukemia; Angiogenesis; Antibody-dependent cellular cytotoxicity; BRAF; BRAF mutation; BRCA1/2; Biliary tract cancers; Biomarkers; Biomedical informatics; Bispecific target engagers (BiTEs); Burkitt lymphoma; CTLA-4; Cancer screening; Checkpoint inhibitor; Chimeric antigen receptor-modified T cells; Chimeric antigen receptor-modified T cells (CAR T); Cholangiocarcinoma; Chromatin; Chronic myeloid leukemia; Circulating tumor DNA; Colorectal cancer; Computer science; Cytogenetics; DMMR; DNA damage repair; DNA methylation; Data science; Diffuse large B-cell lymphoma; EGFR; Epigenetics; Epigenome; Epigenomics; Epithelial ovarian cancer; Esophageal cancer; Evaluation; FLT3; Family health history; Follicular lymphoma; Gallbladder cancer; Gastric cancer; Gene expression profile; Genomics; Germline mutations; HER2; Hepatocellular carcinoma; Heterogeneity; Histone modifications; Homologous recombination deficiency; IDH1; IDH2; Ibrutinib; Immune checkpoint blockade; Immune response; Immune therapy; Immunotherapy; KRAS; Kidney cancer; Lung cancer; Lymphoma; M1/M2 macrophages; MET; MSI-H; Mantle cell lymphoma; Melanoma; Metabolomics; Molecular alteration; Molecular diagnostics; Molecular heterogeneity; Molecular profiling; Molecular tumor board; Myeloid neoplasms; NRAS; NTRK; Next generation sequencing; Next-generation sequencing; PARP inhibitors; PD1/PD-L1; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Patient-entered data; Precision medicine; Precision oncology; Prevention; Prostate cancer; Proteomics; Qualitative research; RET; ROS1; Renal carcinoma; Research design; Risk assessment; Risk prediction; Sequencing; Small molecule inhibitor; Targeted therapy; Transcriptomics; Tumor mutational burden
